Evidence map›Paper›PMID 27010826›Full record

ArticlePLoS genetics2016

Mice Lacking Endoglin in Macrophages Show an Impaired Immune Response.

Luisa Ojeda-Fernández, Lucía Recio-Poveda, Mikel Aristorena, Pedro Lastres, Francisco J Blanco, Francisco Sanz-Rodríguez, Eunate Gallardo-Vara, Mateo de las Casas-Engel, Ángel Corbí, Helen M Arthur and 2 more

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 60 citations in OpenAlex.

  1. Case Report: A pediatric case of multifocalFrontiers in pediatrics · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Loss of growth differentiation factor 15 exacerbates lung injury in neonatal mice.American journal of physiology. Lung cellular and molecular physiology · 2023
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Endoglin in the Spotlight to Treat Cancer.International journal of molecular sciences · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Luisa Ojeda-FernándezCentro de Investigación en Red de Enfermedades Raras (CIBERER), Valencia, Spain.
Lucía Recio-PovedaCentro de Investigaciones Biológicas, Consejo Superior de Investigaciones Biológicas (CSIC), Madrid, Spain.
Mikel AristorenaCentro de Investigaciones Biológicas, Consejo Superior de Investigaciones Biológicas (CSIC), Madrid, Spain.
Pedro LastresCentro de Investigaciones Biológicas, Consejo Superior de Investigaciones Biológicas (CSIC), Madrid, Spain.
Francisco J BlancoCentro de Investigación en Red de Enfermedades Raras (CIBERER), Valencia, Spain.
Francisco Sanz-RodríguezUniversidad Autónoma de Madrid, Madrid, Spain.
Eunate Gallardo-VaraCentro de Investigaciones Biológicas, Consejo Superior de Investigaciones Biológicas (CSIC), Madrid, Spain.
Mateo de las Casas-EngelCentro de Investigaciones Biológicas, Consejo Superior de Investigaciones Biológicas (CSIC), Madrid, Spain.
Ángel CorbíCentro de Investigaciones Biológicas, Consejo Superior de Investigaciones Biológicas (CSIC), Madrid, Spain.
Helen M ArthurInstitute of Genetic Medicine, Newcastle University, Newcastle, United Kingdom.
Carmelo BernabeuCentro de Investigación en Red de Enfermedades Raras (CIBERER), Valencia, Spain.
Luisa M BotellaCentro de Investigación en Red de Enfermedades Raras (CIBERER), Valencia, Spain.
Centro de Investigaciones Biológicas Margarita Salas · ESCentre for Biomedical Network Research on Rare Diseases · ESInstituto de Investigación de Enfermedades Raras · ESNewcastle University · GBUniversidad Autónoma de Madrid · ES

Funding

British Heart Foundation PG/14/86/31177British Heart Foundation RG/12/2/29416
6 · The paper itself

Abstract

Endoglin is an auxiliary receptor for members of the TGF-β superfamily and plays an important role in the homeostasis of the vessel wall. Mutations in endoglin gene (ENG) or in the closely related TGF-β receptor type I ACVRL1/ALK1 are responsible for a rare dominant vascular dysplasia, the Hereditary Hemorrhagic Telangiectasia (HHT), or Rendu-Osler-Weber syndrome. Endoglin is also expressed in human macrophages, but its role in macrophage function remains unknown. In this work, we show that endoglin expression is triggered during the monocyte-macrophage differentiation process, both in vitro and during the in vivo differentiation of blood monocytes recruited to foci of inflammation in wild-type C57BL/6 mice. To analyze the role of endoglin in macrophages in vivo, an endoglin myeloid lineage specific knock-out mouse line (Eng(fl/fl)LysMCre) was generated. These mice show a predisposition to develop spontaneous infections by opportunistic bacteria. Eng(fl/fl)LysMCre mice also display increased survival following LPS-induced peritonitis, suggesting a delayed immune response. Phagocytic activity is impaired in peritoneal macrophages, altering one of the main functions of macrophages which contributes to the initiation of the immune response. We also observed altered expression of TGF-β1 target genes in endoglin deficient peritoneal macrophages. Overall, the altered immune activity of endoglin deficient macrophages could help to explain the higher rate of infectious diseases seen in HHT1 patients.

Indexed as

Activin Receptors, Type IActivin Receptors, Type IIAnimalsEndoglinFlow CytometryGene Expression RegulationHumansImmunity, InnateInflammationIntracellular Signaling Peptides and ProteinsMacrophagesMiceMice, KnockoutOpportunistic InfectionsPhagocytosisTelangiectasia, Hereditary HemorrhagicActivin Receptors, Type IActivin Receptors, Type IIAcvrl1 protein, mouseEndoglinEng protein, mouseIntracellular Signaling Peptides and ProteinsTransforming Growth Factor beta

Identifiers

PMID27010826
PMCPMC4806930
OpenAlexW2310873671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.